Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
Johnson MA, Varanasi SK, Mangalhara KC, Lande K, Rojas GR, Esparza-Moltó PB, Reynolds MB, Olliffe N, Wessendorf-Rodriguez K, Ghosh S, Chen D, Moyzis AG, Donnelly MP, Chinn R, Xu Z, Grae KJ, Tripple V, LaPorta MA, Metallo CM, Hargreaves DC, Kaech SM, Shadel GS. Chronic type II interferon promotes tumor growth through mitochondrial RNA-induced type I interferon and prostaglandin synthesis. Science. 2026 Sep 10; 393(6816):1107-1116.
-
Zhang S, Li M, Liu M, Patten ND, Labaf M, Jeong J, Sun H, Lourie J, Zou K, Patalano S, Mulhearn MJ, Macoska JA, Gao S, Andreotti R, Pennuto M, Han D, Balk SP, Cai C. Minimal-length CAG repeats in AR define a hyperactive AR-LSD1 axis driving metabolic reprogramming in prostate cancer. Proc Natl Acad Sci U S A. 2026 Sep 15; 123(37):e2534152123.
-
Ye T, Alamgir A, Robertus CM, Colina D, Monticello C, Donahue TC, Bandi C, Hong L, Vincoff S, Goel S, Lam K, Heyes J, Putnam D, Alabi CA, Chatterjee P, DeLisa MP. Programmable protein degraders enable selective knockdown of pathogenic ?-catenin subpopulations in vitro and in vivo. Sci Adv. 2026 Aug 28; 12(35):eaec8271.
-
Yang L, Raza F, Song J, Xi X, Yang S, Xiao H, Jiang L, Chen W, Zhong J, Qiu M, Su J. Copper arsenite-loaded hydrogel for breast cancer therapy via cuproptosis-induced immunity synergized with arsenic chemotherapy. Colloids Surf B Biointerfaces. 2026 Dec; 268(Pt 1):116023.
-
Yuan Y, Lu Y, Han X, Zhang Y, Guo Q, Yao H, Yu Q, Zhou M, Huang X, Wang H, Niu M, Yin J, Rong H, Huang L, Li X, Xu S, Zheng L. ISGylation-mediated stabilization of CYP4Z1 fuels breast cancer initiation and progression. Exp Mol Med. 2026 Jul; 58(7):2202-2222.
-
Kane GI, Diaz-Infante MB, Wigglesworth K, Lusi E, Brassil M, Rozen EJ, Kady J, Mori H, Lukas J, Naylor T, Dinnell RW, Murphy KC, Alarcon CBB, Ruscetti M, Brehm M, Shohet JM, Atukorale PU. Tumor Homing Nanoparticle Immunotherapy for Acute Clearance and Mitigation of T-cell Exhaustion in Humanized High-Risk Neuroblastoma. Mol Cancer Ther. 2026 Jul 02; 25(7):1144-1156.
-
Deshpande C, Khanduja S, Rondthaler SN, Andrews LB, Forbes NS. Suppression of Salmonella Effectors with CRISPRi Controls the Immune Response to Bacterial Therapies. ACS Synth Biol. 2026 Jul 17; 15(7):2912-2924.
-
Das A, Malley R, Bailes JE, Bobustuc GC, Varma AK, Lindhorst SM, Cachia D. Effects of Galectin-3 inhibitors paired with direct current stimulation in preclinical models of aggressive meningioma. Mol Biol Rep. 2026 Jun 27; 53(1).
-
Dong Y, Liu M, Gao R, Li M, Zhai J, Cai C, Gao S. Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer. Commun Biol. 2026 Jun 23; 9(1).
-
Parikh CN, DeMarco KD, Bhalerao N, Giwa HK, Kane GI, Dinnell RW, Ma B, Mori H, Brassil ML, Murphy KC, Zhao Z, Johnson C, Ramani S, Zhou L, Chibaya L, Qiao Y, Hu K, Zhu LJ, Lewis BC, Xue W, Pitarresi JR, Atukorale PU, Ruscetti M. Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer. Nat Commun. 2026 Jun 19; 17(1).